BiotechTube

SRP-9005 + Corticosteroid

Phase 3Withdrawn
0 watching 0 views this week📈 Rising
72
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Muscular Dystrophies, Limb-Girdle

Conditions

Muscular Dystrophies, Limb-Girdle

Trial Timeline

Jun 30, 2025 → Mar 30, 2032

NCT ID
NCT06952686

About SRP-9005 + Corticosteroid

SRP-9005 + Corticosteroid is a phase 3 stage product being developed by Sarepta Therapeutics for Muscular Dystrophies, Limb-Girdle. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT06952686. Target conditions include Muscular Dystrophies, Limb-Girdle.

Hype Score Breakdown

Clinical
27
Activity
18
Company
5
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT06952686Phase 3Withdrawn

Competing Products

20 competing products in Muscular Dystrophies, Limb-Girdle

See all competitors
ProductCompanyStageHype Score
Phase 1, SQY51 + Phase 2a, SQY51 (cohort 1) + Phase 2a, SQY51 (cohort 2) + Phase 2a, SQY51 (cohort 3)BiotrialPhase 1/2
33
ENTR-601-44 + ENTR-601-44 - matching placeboEntrada TherapeuticsPhase 1/2
33
ENTR-601-45 + ENTR-601-45 - matching placeboEntrada TherapeuticsPhase 1/2
33
Tadalafil + PlaceboEli LillyPhase 3
77
DS-5141bDaiichi SankyoPhase 2
52
DS-5141bDaiichi SankyoPhase 1/2
41
Bocidelpar + PlaceboAstellas PharmaPhase 1
33
scAAV9.U7.ACCAAstellas PharmaPhase 1/2
41
Placebo + Reldesemtiv 150 mg + Reldesemtiv 450 mgAstellas PharmaPhase 2
52
LY2495655 + PlaceboEli LillyPhase 2
52
HRS-9190; under Inhalational Anesthesia + HRS-9190; under Intravenous Anesthesia + Cisatracurium (under Inhalational Anesthesia). + Cisatracurium (under Intravenous Anesthesia)Jiangsu Hengrui MedicinePhase 2
52
HRS-9190 + HRS-9190 + HRS-9190 + HRS-9190 + Rocuronium + RocuroniumJiangsu Hengrui MedicinePhase 2
52
HRS-9190 + HRS-9190 + HRS-9190Jiangsu Hengrui MedicinePhase 2
52
NS-065/NCNP-01Nippon ShinyakuPhase 2
52
Viltolarsen + PlaceboNippon ShinyakuPhase 3
77
ViltolarsenNippon ShinyakuPhase 2
52
NS-089/NCNP-02 + NS-089/NCNP-02Nippon ShinyakuPhase 2
52
NS-065/NCNP-01Nippon ShinyakuPhase 1
33
NS-050/NCNP-03 + PlaceboNippon ShinyakuPhase 1/2
41
NS-089/NCNP-02Nippon ShinyakuPhase 2
52

Other Products from Sarepta Therapeutics

Golodirsen 50 MG/1 ML Intravenous Solution [VYONDYS 53]Approved
80
EteplirsenPhase 3
72
Casimersen + GolodirsenPhase 3
72
SRP-9003 + GlucocorticoidPhase 3
72
eteplirsenPhase 3
72